» Articles » PMID: 39590163

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer

Abstract

The accurate staging of breast cancer is fundamental for guiding treatment decisions and predicting patient outcomes. However, there can be considerable variation in routine clinical practice based on individual interpretation of guidelines and depending on the healthcare provider initially involved in working up patients newly diagnosed with breast cancer, ranging from primary care providers, triage nurses, surgeons, and/or oncologists. The optimal approach for clinical staging, particularly in asymptomatic patients presenting with intermediate-risk disease, remains a topic of dialogue among clinicians. Given this area of uncertainty, the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance conducted a modified Delphi process to assess the level of agreement among Canadian expert clinicians on various staging recommendations. In total, 20 items were drafted covering staging based on biological status, the utilization of localization clips, both for the axilla during diagnosis and primary surgical site for margins and radiation therapy planning, and the use of advanced imaging for the investigation of distant metastases. Overall, the consensus threshold among all participants (i.e., ≥75% agreement) was reached in 20/20 items. Differences in clinical practice and recent findings from the literature are provided in the discussion. These consensus recommendations are meant to help standardize breast cancer staging practices in Canada, ensuring accurate diagnosis and optimal treatment planning.

References
1.
Kamel D, Youssef V, Hopman W, Mates M . Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario. Curr Oncol. 2021; 28(3):2190-2198. PMC: 8293210. DOI: 10.3390/curroncol28030203. View

2.
van Maaren M, de Munck L, Strobbe L, Sonke G, Westenend P, Smidt M . Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2018; 144(2):263-272. DOI: 10.1002/ijc.31914. View

3.
Voduc K, Cheang M, Tyldesley S, Gelmon K, Nielsen T, Kennecke H . Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10):1684-91. DOI: 10.1200/JCO.2009.24.9284. View

4.
Bezerra C, Grande A, Galvao V, Santos D, Atallah A, Silva V . Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study. Sao Paulo Med J. 2022; 140(6):829-836. PMC: 9671561. DOI: 10.1590/1516-3180.2022.0043.R1.07042022. View

5.
Dayes I, Metser U, Hodgson N, Parpia S, Eisen A, George R . Impact of F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. J Clin Oncol. 2023; 41(23):3909-3916. DOI: 10.1200/JCO.23.00249. View